Hyderabad-based drug firm Suven Life Sciences Limited has secured five product patents for their new chemical entities (NCEs) in China & Korea for the treatment of disorders associated with neurodegenerative diseases like Alzheimer's disease, attention deficient hyperactivity disorder, huntington's disease, parkinson and schizophrenia.
These patents are valid through 2007 and 2028 respectively, the company said in a filing to the Bombay Stock Exchange (BSE). It includes three patents from China and two from Korea, and takes the total number to eight patents from China and ten from Korea so far.
Products out of these inventions through internal discovery research efforts may be out-licensed at various phases of clinical development like phase I and phase II, the release said.
Suven has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage under its portfolio.
The company's scrip is currently trading at Rs 34.10 on BSE, up 3.02% over the previous close of Rs 33.11.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app